SCHEMBL2935561

SCHEMBL2935561

Cc1cc(O)cc2c1CCC(=O)O2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.42
ALDH2 P05091 1/20 0.39
ALDH3A1 P30838 1/20 0.39
KMT2A Q03164 6/20 0.38
MEN1 O00255 5/20 0.38
MAPT P10636 3/20 0.38
THRB P10828 2/20 0.38
USP2 O75604 2/20 0.38
HPGD P15428 3/20 0.37
GLA P06280 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 3/20 0.35
TSHR P16473 1/20 0.34
POLB P06746 2/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832823 0.81 ALDH2 (0.41) ALDH2ALDH3A1MAPTHPGDGLA
SCHEMBL30748275 0.81 ALDH1A1 (0.43) KMT2AMEN1MAPTHPGDGLA
SCHEMBL2929767 0.81 ALDH1A1 (0.43) KMT2AMEN1MAPTHPGDGLA
SCHEMBL6836704 0.76 ALDH2 (0.37) ALDH2ALDH3A1HPGDGLAKDM4E
SCHEMBL18721194 0.76 PTPN1 (0.40) KMT2AMEN1HPGDGLAKDM4E
SCHEMBL21143149 0.75 GLA (0.37) ALDH2ALDH3A1KMT2AMEN1MAPT
SCHEMBL15800840 0.75 KDM4E (0.34) KMT2AMEN1HPGDGLAKDM4E
SCHEMBL11013926 0.72 KDM4E (0.38) ALDH2ALDH3A1KMT2AMEN1HPGD
SCHEMBL30067255 0.72 PBRM1 (0.46) KMT2AMEN1MAPTTHRBHPGD
SCHEMBL5547659 0.72 MAOA (0.41) CYP19A1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022256480-A1 ARYLCOUMARIN SYNTHESIS WITH AZEOTROPIC REMOVAL OF WATER CONAGEN INC. (US) 2022-12-08 WO disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
EP-2229169-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES Merck Patent GmbH (DE) 2010-09-22 EP disclosed
WO-2009089880-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-07-23 WO disclosed
WO-2009089880-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-07-23 WO disclosed
US-4542150-A INSECTICIDES CORNELL RESEARCH FOUNDATION, INC. (US) 1985-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES RCC1, RB1, RCC2 CYP19A1 316/4885ALDH2 3443/4885ALDH3A1 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.